Linker Information
General Information of This Linker
| Linker ID |
LIN0QBMVS
|
|||||
|---|---|---|---|---|---|---|
| Linker Name |
A cleavable but systemically stable linker
|
|||||
| Linker Type |
Unclear
|
|||||
| Antibody-Linker Relation |
Cleavable
|
|||||
Each Antibody-drug Conjugate Related to This Linker
Full Information of The Activity Data of The ADC(s) Related to This Linker
BAT8007 [Phase 1 (discontinued)]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Eligible patients (18-75 years, ECOG 0-1) must have advanced solid tumors failing standard therapy, measurable lesions per RECIST 1.1, and adequate organ function. Key exclusions include prior Nectin-4 treatment, uncontrolled cardiovascular disease (NYHA≥2, QTc>450/470ms), active HIV/HBV/HCV/syphilis, untreated tuberculosis, recent major surgery/thromboembolism, or live vaccinations within 4 weeks. COVID-19 vaccination requires ≥14-day separation from treatment initiation.
Click to Show/Hide
|
||||
| Administration Dosage |
Subjects with advance solid tumor received BAT8007 on day 1 of a 21-day cycle until subject intolerance or disease progression.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT05879627 | Clinical Status | PHASE1 | ||
| Clinical Description |
A Multicenter, Open Phase I Clinical Study to Evaluate the Safety, Tolerance and Pharmacokinetics of BAT8007 for Injection in Patients With Advanced Solid Tumors
|
||||
| Primary Endpoint |
The study will assess dose-limiting toxicities (DLTs) within 21 days post-initial BAT8007 dose using NCI CTCAE v5.0, alongside continuous adverse event (AE) monitoring from first dose to 28 days post-treatment or until new antitumor therapy begins.
|
||||
| Other Endpoint |
Immunogenicity (ADA levels) and neutralizing antibodies (NAb) will be tracked through Cycle 3 (14-day cycles), alongside pharmacokinetic analyses including Cmax, Tmax, T1/2, and systemic clearance.
|
||||
References